According to the market intelligence report titled ‘GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2021-2028’, available with MarketStudyReport, global Alzheimer’s disease therapeutics and diagnostics market is slated to progress at a CAGR of over 5.56% during the analysis period of 2021-2028.
 

Increasing number of patients with dementia in developing countries along with rising number of clinical trials and new drug launches are facilitating global Alzheimer’s disease therapeutics and diagnostics market growth. Further, the emergence of novel diagnostic technologies plays a crucial role in broadening the horizon of the business.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4345811/  

Despite the positive industry outlook, challenges like low efficacy of late-stage drugs and a stringent regulatory landscape with respect to clinical trials and drug development may negatively impact growth patterns in the forthcoming years.

Moving on to segmentation, the business sphere is fragmented in terms of therapeutics, diagnostics and region.

Based on therapeutics, the industry is further divided in terms of drugs (marketed, pipeline), disease stage (prodromal, early/middle, late), and brand (generic, branded).

Speaking of diagnostics, the industry is bifurcated into electroencephalography, position emission tomography, lumbar puncture test, computed tomography, magnetic resonance imaging, and blood tests among others.

Geographically, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa are the major contributors to the global Alzheimer’s disease therapeutics and diagnostics industry development. Among these, North America holds a majority of the market share and is anticipated to maintain a strong growth curve during the evaluation period owing to rising prevalence of elderly population in the region.

Verifiable statistics prove that 1 in 9 people suffers from dementia in the United States. In addition, prevailing research studies that focus on prolonging deterioration among patients with dementia as well as penetration of new drugs play a vital role are pushing the regional industry forward.

Novartis International AG, GE Healthcare, Luye Pharma Group Ltd, Zydus Cadila Limited, PeopleBio Co., Pfizer Inc., Lupin Ltd., Johnson & Johnson, Baxter International Inc., Merck & Co. Inc., Teva Pharmaceutical Industries, Eli Lilly & Company, Cognoptix Inc., Amarantus BioScience Holdings Inc., and Allergan Plc are some of the prominent players influencing worldwide Alzheimer’s disease therapeutics and diagnostics industry dynamics.